Venmax Drugs and Pharmaceuticals Ltd — Important, 03-09-2025: Company Update

The Board approved a strategic amalgamation of Hatri Pharma Private Limited (HPPL) with Venmax Drugs and Pharmaceuticals Limited (VDPL). This merger aims to enhance operational efficiency, reduce costs, and achieve backward integration by combining VDPL's pharmaceutical trading with HPPL's manufacturing capabilities. HPPL reports a net worth of 16.44 Cr and turnover of 16.45 Cr, while VDPL has a net worth of 8.04 Cr and turnover of 2.53 Cr. Shareholders of HPPL will receive one VDPL share for each HPPL share held. Additionally, the Board approved increasing the authorized share capital from 22 Cr to 60 Cr, subject to shareholder approval.